MXPA02012896A - Combinations of statins, estrogenic agents and optionally estrogens. - Google Patents
Combinations of statins, estrogenic agents and optionally estrogens.Info
- Publication number
- MXPA02012896A MXPA02012896A MXPA02012896A MXPA02012896A MXPA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A
- Authority
- MX
- Mexico
- Prior art keywords
- statins
- combinations
- estrogenic agents
- estrogens
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21618400P | 2000-07-06 | 2000-07-06 | |
| US21609600P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/021085 WO2002003977A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012896A true MXPA02012896A (en) | 2003-10-24 |
Family
ID=26910656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012896A MXPA02012896A (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1359940A2 (en) |
| JP (1) | JP2004502731A (en) |
| CN (1) | CN1468110A (en) |
| AU (1) | AU2001271785A1 (en) |
| BR (1) | BR0112365A (en) |
| CA (1) | CA2414060A1 (en) |
| MX (1) | MXPA02012896A (en) |
| WO (1) | WO2002003977A2 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2504682A1 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| LT3355884T (en) | 2015-10-01 | 2021-07-26 | Olema Pharmaceuticals, Inc. | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| CA3008020C (en) | 2015-12-09 | 2024-02-20 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
| BR112018077136A2 (en) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | compound, and methods for treating a disorder associated with abnormal cell proliferation and for reducing the effect of chemotherapy on healthy cells. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| IL267795B2 (en) | 2017-01-06 | 2023-02-01 | G1 Therapeutics Inc | Combined treatment for cancer |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EA201992768A1 (en) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | MORPHOLOGICAL FORMS G1T38 AND METHODS FOR PRODUCING THEM |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| KR20220034129A (en) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | Estrogen receptor antagonist therapy |
| JP7757284B2 (en) | 2019-12-20 | 2025-10-21 | シーフォー セラピューティクス, インコーポレイテッド | Isoindolinone and indazole compounds for degradation of EGFR |
| BR112022017393A2 (en) | 2020-03-05 | 2022-10-18 | C4 Therapeutics Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD TO TREAT A BRD9-mediated DISORDER, AND, USE OF A COMPOUND |
| CA3188313A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
| CA3174245A1 (en) | 2021-06-08 | 2022-12-15 | Christopher G. Nasveschuk | Therapeutics for the degradation of mutant braf |
| EP4565585A1 (en) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Compounds for modulating ret protein |
| EP4611900A1 (en) | 2022-11-04 | 2025-09-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515484A (en) * | 1998-05-15 | 2002-05-28 | アメリカン・ホーム・プロダクツ・コーポレイション | Composition comprising 2-phenylindole compound and estrogen preparation |
| UA66861C2 (en) * | 1998-05-15 | 2004-06-15 | Уайт | 2-phenyl-1-[4-(2-aminoeihoxy)benzyl]-indole in combination with estrogens, method for treatment and pharmaceutical product |
-
2001
- 2001-06-29 AU AU2001271785A patent/AU2001271785A1/en not_active Abandoned
- 2001-06-29 CA CA002414060A patent/CA2414060A1/en not_active Abandoned
- 2001-06-29 BR BR0112365-3A patent/BR0112365A/en not_active IP Right Cessation
- 2001-06-29 EP EP01950826A patent/EP1359940A2/en not_active Withdrawn
- 2001-06-29 MX MXPA02012896A patent/MXPA02012896A/en unknown
- 2001-06-29 CN CNA018150896A patent/CN1468110A/en active Pending
- 2001-06-29 JP JP2002508432A patent/JP2004502731A/en active Pending
- 2001-06-29 WO PCT/US2001/021085 patent/WO2002003977A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003977A2 (en) | 2002-01-17 |
| CN1468110A (en) | 2004-01-14 |
| JP2004502731A (en) | 2004-01-29 |
| CA2414060A1 (en) | 2002-01-17 |
| WO2002003977A3 (en) | 2003-09-04 |
| EP1359940A2 (en) | 2003-11-12 |
| BR0112365A (en) | 2003-05-13 |
| AU2001271785A1 (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012896A (en) | Combinations of statins, estrogenic agents and optionally estrogens. | |
| MXPA02012897A (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens. | |
| AU5208401A (en) | 3-nitrogen-6,7-dioxygen steroids and uses related thereto | |
| MXPA02012891A (en) | Pharmaceutical compositions of estrogenic agents. | |
| MXPA03000499A (en) | Wireless electrocardiograph system and method. | |
| ZA200203316B (en) | New use and novel n-azabicyclo-amide derivatives. | |
| MXPA03005445A (en) | I2. | |
| ZA200204165B (en) | Fulvestrant formulation. | |
| MXPA03002410A (en) | 4-amino-quinazolines. | |
| MXPA03001983A (en) | Exemestane as chemopreventing agent. | |
| ZA200207489B (en) | Apomorphine derivatives and methods for their use. | |
| EG23373A (en) | Process and intermediates. | |
| MXPA03003522A (en) | Diaper. | |
| EG23262A (en) | Delta -pyrrolines. | |
| ZA200302014B (en) | Methods and compositions for promoting the maturation of monocytes. | |
| MXPA03001591A (en) | 10-aryl-11-h. | |
| IL144455A0 (en) | 16-hydroxyestratrienes as selective estrogens | |
| MXPA03001877A (en) | 2-guanidino-4-aryl-quinazoline. | |
| MXPA03002668A (en) | Sulfonylguanidine. | |
| MXPA03005714A (en) | Sulfamidothienopyrimidines. | |
| MXPA03002411A (en) | 4-amino-quinazolines. | |
| MXPA03005494A (en) | Benzoylpyridazines. | |
| MXPA03002521A (en) | Triazolo-epothilones. | |
| MXPA01000464A (en) | Composition. | |
| ZA200300417B (en) | 16alpha-methyl or ethyl substituted estrogens. |